| 2-AG | 2-ArachidonoylGlycerol |
| AA | Arachidonic Acid |
| ACR | American College of Rheumatology |
| ACTH | Adrenocorticotropic hormone |
| AEA | N-arachidonoylethanolamine |
| BDNF | Brain-Derived Neurotrophic Factors |
| CB1 | Cannabinoid Receptor 1 |
| CB2 | Cannabinoid Receptor 2 |
| CBD | Cannabidiol |
| CNS | Central Nervous System |
| EA | Electro-Acupuncture |
| ESS | Extent of Somatic Symptoms |
| FIQ | FM Impact Questionnaire |
| FIQR | FM Impact Questionnaire Revised version |
| FM | Fibromyalgia |
| FS | Fibromyalgianess Scale |
| GABA | Gamma-Aminobutyric Acid |
| GRADE | Grading of Recommendations, Assessment, Development, and Evaluation |
| HBOT | Hyperbaric Oxygen Therapy |
| ICD-11 | International Classification of Diseases |
| IL-1β | Interleukin 1 beta |
| IL-6 | Interleukin 6 |
| MA | Manual Acupuncture |
| PEA | Palmitoylethanolamide |
| PFM | Primary FM |
| ROS | Reactive Oxygen Species |
| SIQ | Symptom Impact Questionnaire |
| SFM | Secondary FM |
| SNRIs | Serotonin and Norepinephrine Reuptake Inhibitors |
| SSRIs | Serotonin Selective Reuptake Inhibitors |
| SSS | Symptom Severity Scale |
| TCAs | Tricyclic Antidepressant |
| TNFα | Tumor necrosis factor alpha |
| VAS | Visual Analog Scale |
| WPI | Widespread Pain Index |
| Δ9-THC | Delta 9-tetrahydrocannabinol |